The Digital Markets, Competition and Consumers Act 2024 (UK DMCC) introduces significant reforms to the UK’s Competition and Markets Authority ...

Qualcomm (NASDAQ:QCOM) – Apollo Global Management has reportedly offered up to $5 billion to invest in Intel, according to ...

Competition could come from established vaccine firms partnering with innovative mRNA firms (GSK/CureVac and Sanofi's Translate acquisition ... firm's rapid development timeline during the ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

BANKS and other lenders are lining up more than 10 billion euros (S$14.3 billion) of debt to back a buyout of Sanofi’s consumer health division ... billion euros of senior debt to back bids for the ...

Sanofi’s Enjaymo, the only approved drug ... company’s rare disease portfolio is comprised of assets from its 2022 acquisition of EUSA Pharma, a developer of drugs for rare cancers.

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...